


Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1329	SERIAL NO. 10/081,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Pen Cho TANG et al.	
		FILING DATE 02/25/2002	GROUP ART UNIT 1626



PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
<i>SNW</i>	A1	3,308,134	03/07/67	PLOSTNIEKS			
	A2	4,002,749	01/11/77	ROVNYAK			
<i>SNW</i>	A3	4,053,613	10/11/77	ROVNYAK et al.			
	A4	4,900,849	10/30/90	VALLEE et al.			
<i>SNW</i>	A5	5,217,999	06/08/93	LEVITZKI et al.			
<i>SNW</i>	A6	5,302,606	04/12/94	SPADA et al.			
<i>SNW</i>	A7	5,330,992	07/19/94	EISSENSTAT et al.			
	A8	5,710,135	02/17/98	BUZZETTI et al.			
	A9	5,786,488	07/28/98	TANG			
	A10	5,792,709	08/11/98	TANG et al.			
	A11	5,840,745	11/24/98	BUZZETTI et al.			
	A12	5,880,141	03/09/99	TANG			
	A13	5,883,113	03/16/99	TANG			
	A14	5,883,116	03/16/99	TANG			
	A15	5,886,020	03/23/99	TANG			
<i>SNW</i>	A16	Re 36,256	07/20/99	SPADA et al.			

RECEIVED
JUL 24 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	A17	91/13055	09/05/91	WIPO				
<i>SNW</i>	A18	91/15495	10/17/91	WIPO				
	A19	92/07830	05/14/92	WIPO				
<i>SNW</i>	A20	92/20642	11/26/92	WIPO				
<i>SNW</i>	A21	92/21660	12/10/92	WIPO				
	A22	93/23040	11/25/93	WIPO				
<i>SNW</i>	A23	94/03427	02/17/94	WIPO				
	A24	94/10202	05/11/94	WIPO				
<i>SNW</i>	A25	94/14808	07/07/94	WIPO				
	A26	95/24490	09/14/95	WIPO				
	A27	96/00226	01/04/96	WIPO				
	A28	96/16964	06/06/96	WIPO				
<i>SNW</i>	A29	96/40116	12/19/96	WIPO				

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1329		SERIAL NO. 10/081,147	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Pen Cho TANG et al.			
				FILING DATE 02/25/2002		GROUP ART UNIT 1626	
SNW	A30	98/07695	02/26/98	WIPO			
	A31	98/07835	02/26/98	WIPO			
SNW	A32	98/24432	06/11/98	WIPO			
SNW	A33	98/38984	09/11/98	WIPO			
	A34	98/45700	10/15/98	WIPO			
	A35	98/50356	11/12/98	WIPO			
	A36	98/56376	12/17/98	WIPO			
	A37	98/10325	04/09/99	WIPO			
SNW	A38	99/48868	09/30/99	WIPO			
SNW	A39	99/61422	02/21/99	WIPO			
	A40	0 252 731 A1	01/13/88	EP			
SNW	A41	0 566 226 A1	10/20/93	EP			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
SNW	A42	AKBASAK et al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)					
	A43	ANDREANI et al., "In Vivo Cardiotoxic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48(III):727-729 (1998)					
	A44	ANDREANI et al., "Synthesis and potential coanthracycline activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997)					
SNW	A45	ARTEAGA et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989)					
SNW	A46	ARVIDSSON et al., "Tyr-716 in the Platelet-Derived Growth Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726					
SNW	A47	BASERGA, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994)					
SNW	A48	BASERGA, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)					
SNW	A49	BOLEN et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)					
SNW	A50	BOLEN, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993)					
SNW	A51	BONNER et al., "Structure and Biological Activity of Human Homologs of the <i>raf/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985)					

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1329	SERIAL NO. 10/081,147
INFORMATION DISCLOSURE CITATION JUL 23 2002 <i>(Use several sheets if necessary)</i>		APPLICANT Pen Cho TANG et al.	
		FILING DATE 02/25/2002	GROUP ART UNIT 1626
A52	BUZZETTI et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48(5):645-630 (1993)		
A53	CANCE et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993)		
A54	CARPENEDO et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997)		
A55	CHEN et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ-Aminobutyric Acid-Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40(3):149-156 (1997)		
A56	CLAESSON-WELSH, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994)		
A57	COPPOLA et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> , 14:4588-4595 (1994)		
A58	DAMIANI et al., "Inhibition of Copper-Mediated Low-Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48(6):1455-1464 (1994)		
A59	Database CAPLUS, An 1998: 151222, abstract for MOHAMMADI et al., Crystal structures of a protein tyrosine kinase, WO 98/07835 (February 26, 1998)		
A60	Database CAPLUS on STN, AN 1998: 147306, abstract for TANG et al., Indolinone combinatorial libraries and related products and methods for the treatment of disease, WO 98/07695 (February 26, 1998)		
A61	Database CAPLUS on STN, AN 1997: 140244, abstract for Tang et al., Indolinone compounds capable of modulating tyrosine kinase signal transduction, WO 96/40146 (December 19, 1996)		
A62	DAVIS et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16(9):1043-1045 (1973)		
A63	DeVRIES et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)		
A64	DECKER et al., "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>Journal of Immunological Methods</u> 15:61-69 (1988)		
A65	DICKSON et al., "Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992)		
A66	EUROPEAN SEARCH REPORT of 99/027120 (Supplementary)		
A67	FANTL et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992)		
A68	FENDLY et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2 neu Gene Product," <u>Cancer Research</u> 50:1550-1556 (1990) (this entry referred to as Fendley)		

JUL 24 2002

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1329		SERIAL NO. 10/081,147	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Pen Cho TANG et al.			
				FILING DATE 02/25/2002		GROUP ART UNIT 1626	
ANW	A69	FERRARA et al., "Pituitary Follin-like Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989)					
ANW	A70	FINGL et al., "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5 th Edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975)					
	A71	FLOECE et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," <u>Kidney International</u> 43:647-654 (1993)					
ANW	A72	FOLKMAN et al., "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992)					
ANW	A73	FOLKMAN, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)					
ANW	A74	FOLKMAN, "Tumor Angiogenesis, Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971)					
ANW	A75	FOLKMAN, "What is evidence that tumors are angiogenesis dependent?" <u>Journal of National Cancer Institute</u> 82:4-6 (1990)					
	A76	GAZIT et al., "Tyrosine-2-Heterocyclic and alpha-substituted benzylidenemalonitrile tyrosine as potent inhibitors of EGF receptor and ErbB2-neu tyrosine kinases," <u>J. Med. Chem.</u> 34(6):1896-1907 (1991)					
ANW	A77	GENNARO (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)					
ANW	A78	GOLDRING et al., "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)					
	A79	GRAZIANI et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide-Exchanger," <u>The Journal of Biological Chemistry</u> 268(19):9165-9168 (1993)					
ANW	A80	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987)					
ANW	A81	HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992)					
ANW	A82	HU et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12(3):981-990 (1992)					
ANW	A83	JELLINEK et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)					
ANW	A84	KASHISHIAN et al., "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cy1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993)					
ANW	A85	KASHISHIAN et al., "Phosphorylation Sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo," <u>The EMBO Journal</u> 11(4):1373-1382 (1992)					

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1329		SERIAL NO. 10/081,147	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Pen Cho TANG et al.			
				FILING DATE 02/25/2002		GROUP ART UNIT 1626	
	A86	KATO et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-74 (1993)					
ANW	A87	KAZLAUSKAS et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor β subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)					
ANW	A88	KENDALL and THOMAS, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor" <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)					
ANW	A89	KIM et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)					
ANW	A90	KINSELLA et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992)					
ANW	A91	KLAGSBRUN and SOKER, "VEGF/VF: the angiogenesis factor found" <u>Current Biology</u> 3:699-702 (1993)					
ANW	A92	KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)					
ANW	A93	KOMADA and KITAMURA, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor" <u>Oncogene</u> 8:2381-2390 (1993)					
ANW	A94	KORC et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992)					
ANW	A95	KORAENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity ¹ ," <u>J. Immunol Methods</u> 64:313-320 (1983)					
ANW	A96	KUMABE et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)					
ANW	A97	LEE and DONOGHUE, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>Journal of Cell Biology</u> 118:1057-1070 (1992)					
	A98	LEVITZKI et al., Tyrosine kinase inhibition: An approach to drug development," <u>Science</u> 267:1762-1768 (1995)					
	A99	MAAGS et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37(12):2612-2617 (1993)					
ANW	A100	MACAULEY et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <u>Cancer Research</u> 50:2511-2517 (1990)					
	A101	MARIANI et al., "Inhibition of angiogenesis by PCE 20000, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:384 at abstract no. 2268 (March 1994)					
ANW	A102	MOHAMMADI et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," <u>Science</u> 276:955-960 (May 1997)					

RECEIVED


JUL 24 2002

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1329		SERIAL NO. 10/081,147	
INFORMATION DISCLOSURE CITE (Use several sheets if necessary)				APPLICANT Pen Cho TANG et al.			
				FILING DATE 02/25/2002		GROUP ART UNIT 1626	
ANW	A103	MILLAUER et al., "High Affinity Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993)					
	A104	MORETO et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (DHM), the Active Metabolite of the Laxative Colisatin," <u>Arzneimittel-Forschung-Drug-Research</u> 29(ii):4564-4564 (1979)					
	A105	MORETO et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (Dan-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976)					
ANW	A106	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983)					
ANW	A107	NISHIMURA et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:689-6896 (1993)					
	A108	INTERNATIONAL SEARCH REPORT for 99/10269					
ANW	A109	PLOWMAN et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)					
ANW	A110	QUINN et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)					
ANW	A111	ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)					
ANW	A112	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta path. microbiol. scand.</u> 77:758-760 (1969)					
ANW	A113	SANDBERG-NORDQVIST et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)					
ANW	A114	SCHLESSINGER and ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992)					
ANW	A115	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <u>Oncogene</u> 5:519-524 (1990)					
	A116	SHIRAIISHI et al., "Specific Inhibitors of Tyrosine Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147(1):322-328 (1987)					
	A117	SINGH et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989)					
	A118	SINGH et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxospiro-(Azetidin-3',4'-Indol-2'-Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)					
ANW	A119	SLAMON et al., "Studies of the HER-2-neu Proto-Oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)					

RECEIVED

JUL 24 2002

TECH CENTER 1600/2900

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 038602-1329	SERIAL NO. 10/081,147
INFORMATION DISCLOSURE NOTIFICATION  (Use several sheets if necessary)		APPLICANT Pen Cho TANG et al.	
		FILING DATE 02/25/2002	GROUP ART UNIT 1626
	A120	SOLDI et al., "Platelet-Derived Growth Factor (PDGF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13(3):615-625 (1996)	
ANW	A121	SONGYANG et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994)	
ANW	A122	SONGYANG et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993)	
	A123	SPADA et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5(8): 805-817 (1995)	
ANW	A124	SUN et al., "Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases," <u>J. Med. Chem.</u> 41(14):2588-2603 (1998)	
ANW	A125	SUN, et al. "Design, Synthesis, and Evaluation of Substituted 3-[(3-or-4-Carboxyethylpyrrol-2-yl)methylidene]indolin-2-ones as "Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> 42:5120-5130 (1999)©American Chemical Society	
ANW	A126	SUPERTI-FURGA et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech</u> 14:600-605 (1996)	
ANW	A127	SUPERTI-FURGA et al., "Csk inhibition of c-Src activity requires both SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993)	
ANW	A128	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)	
ANW	A129	Torp et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>AMJIS</u> 100:713-719 (1992)	
	A130	TRAXLER, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997)	
	A131	TSAL et al., "The Effect of 3,3-Di-Pyridyl Methyl 1-Phenyl 2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31(9):943-947 (1992)	
ANW	A132	TUZI et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)	
ANW	A133	TWAMLEY-STEIN et al., "The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells," <u>Proc. Natl. Acad. Sci.</u> 90:7696-7700 (1993)	
ANW	A134	VAISMAN et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem</u> 265:19461-19466 (1990)	
	A135	VARMA et al., "Nucleophilic Reactions of 2-Methyl 3-(4'-carboxymethoxyphenyl) 4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989)	
ANW	A136	Voller et al., "Ch. 45 - Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 259-277 (1980)	

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602-1329		SERIAL NO. 10/081,147	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Pen Cho TANG et al.			
				FILING DATE 02/25/2002		GROUP ART UNIT 1626	
	A137	WALKER, "The Reaction of Insecticides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8(5):626-631 (1965)					
DNW	A138	Weidner et al., "Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma," <u>New England Journal of Medicine</u> 324(1):1-8(1991)					
DNW	A139	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)					
	A140	ZAMAN et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57(1):57-64 (1999)					
	A141	ZHANG et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug-Resistance," <u>Molecular Pharmacology</u> 49:228-294 (1996)					
EXAMINER Sonya Wright				DATE CONSIDERED 11-25-02			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

RECEIVED
JUL 24 2002
TECH CENTER 1600/2900